Healthcare Industry News: Acute Coronary Syndrome
News Release - February 3, 2012
Prometheus Announces New Chief Commercial OfficerSAN DIEGO, Feb. 3, 2012 -- (Healthcare Sales & Marketing Network) -- Prometheus Laboratories Inc., a specialty pharmaceutical and diagnostic company, today announced the appointment of Anthony J. Yost as Senior Vice President and Chief Commercial Officer.
Tony joins Prometheus with a proven track record of almost 30 years in the healthcare industry. Most recently, Tony was with EKR Therapeutics, where he served as Chief Commercial Officer and was responsible for all commercial activities in the acute care market. Prior to joining EKR, Tony was General Manager for the Western U.S. Operating Unit of Novartis Pharmaceuticals, where he oversaw all commercial operations within the operating unit, including, but not limited to Primary Care and Specialty Sales Teams, Managed Markets, Operations and Business Planning & Strategy. Prior to Novartis, Tony was President of Innovex, the commercial solutions division of Quintiles Transnational. Tony also had various responsibilities at Schering-Plough Pharmaceuticals, where he served in the capacities of Vice President, Acute Coronary Syndromes Business Unit, General Manager of Commercial and Manufacturing Operations for Schering-Plough in Portugal, Vice President of Managed Care and Vice President, Cardiovascular Business Unit. Additional industry experience includes Boehringer Mannheim Pharmaceuticals and Eli Lilly and Company. Tony received a Bachelors of Science in Pharmacy from Purdue University.
"We are pleased to welcome Tony to the Prometheus management team," said Joseph M. Limber, President and Chief Executive Officer of Prometheus. "His impressive background in healthcare sales and marketing, new product planning and strategic analysis, as well as his leadership capabilities, will be pivotal to the continued commercial success of Prometheus."
Prometheus Laboratories Inc. is committed to improving lives through the development and commercialization of novel pharmaceutical and diagnostic products that enable physicians to provide greater individualized patient care. Prometheus is a leader in applying the principles of personalized medicine to the diagnosis and treatment of gastrointestinal diseases and is applying these principles to oncology. Its strategy includes the marketing and delivery of pharmaceutical products complemented by proprietary diagnostic testing services. By integrating therapeutics and diagnostics, Prometheus believes it can provide physicians with more targeted solutions to optimize care for their patients. Prometheus became part of Nestle Health Science in July 2011. Prometheus' corporate offices are located in San Diego, California. For more information about Prometheus, please visit www.prometheuslabs.com.
About Nestle Health Science
Nestle Health Science, a fully-owned subsidiary of Nestle S.A., is operational since January 1, 2011 and has worldwide headquarters in Lutry, Switzerland. Nestle Health Science offers nutritional solutions for people with specific dietary needs related to illnesses, disease states or the special challenges of different life stages. For more information about Nestle Health Science, please visit www.nestlehealthscience.com.
Source: Prometheus Laboratories
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.